Employers Hold the Line on GLP-1 Weight Loss Drug Coverage
Most employers are not expanding GLP-1 obesity drug benefits, with coverage holding flat at 36% for two consecutive years.
Employer coverage of GLP-1 drugs for weight loss has stalled, with a new survey showing that roughly 36% of companies cover the medications for both diabetes and obesity — unchanged from 2025 and only marginally higher than the 34% recorded in 2024. The plateau signals that businesses are resisting pressure to expand benefits for a class of drugs that has generated enormous consumer demand but carries steep price tags.
Rather than broadening access, many employers appear to be finding workarounds to limit their financial exposure to GLP-1s, which include blockbuster treatments like Ozempic and Wegovy. Those strategies can range from imposing prior authorization requirements to steering employees toward lifestyle management programs as prerequisites for drug coverage.
Read more Employers Hold the Line on GLP-1 Coverage for Weight Loss →
The flat coverage numbers come even as GLP-1 medications have dominated public health conversations and driven record prescription volumes across the United States. Analysts have noted that the cost burden on self-insured employers remains a significant barrier, with annual per-patient costs for weight-loss-indicated GLP-1s running into the thousands of dollars.
The data suggest that without meaningful price reductions or negotiated rebates, widespread employer adoption of GLP-1 obesity coverage is unlikely to accelerate in the near term. Workers seeking these treatments may increasingly find themselves navigating narrow benefit structures or covering costs out of pocket.
Continue reading at US Top News and Analysis.
